GENE THERAPY AND PANCREATIC CANCER

A. Scott Pearson, Michael Bouvet, Douglas B. Evans, and Jack A. Roth

Departments of Surgical Oncology (ASP, MB, DBE) and Thoracic and Cardiovascular Surgery (JAR), The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Received 6/25/98 Accepted 7/7/98

TABLE OF CONTENTS

1. Abstract

2. Introduction

3. Molecular Biologic Targets in Pancreatic Cancer

3.1. p53
3.2. K-ras
3.3. DPC-4, p16, and Rb
3.4. Bcl-2
3.5. Others

4. Methods for Gene Transfer

4.1. Viruses

4.1.1. Retroviruses
4.1.2. Adenoviruses
4.1.3. Adeno-associated viruses

4.2. Liposomes
4.3. Naked DNA technology

5. Manipulation of Genetic Targets

5.1. Restoration of Tumor Suppressor Genes and Anti-Oncogene Strategies

5.1.1. Gene Overexpression
5.1.2. Antisense, Ribozymes, and Drug Susceptibility Genes

5.2. Immunotherapy
5.3. Bystander Effect

6. Measuring Response to Gene Therapy

6.1. Gene Expression
6.2. Apoptosis and Cell cycle Arrest

7. Current Status of Pre-clinical Gene Therapy Studies in Pancreatic Cancer

8. Perspective

9. Acknowledgments

10. References

11. Entire Manuscript

Key Words: Gene Therapy, Pancreatic Cancer, p53, K-ras, adenovirus Search OMIM (Online Mendelian Inheritance in Man) to find related articles
This form requires a WWW Client such as Netscape, XMosaic, Lynx that supports fill-in forms.